HRP20120681T1 - Stabilni kristal 4-oksokinolinskog spoja - Google Patents

Stabilni kristal 4-oksokinolinskog spoja Download PDF

Info

Publication number
HRP20120681T1
HRP20120681T1 HRP20120681TT HRP20120681T HRP20120681T1 HR P20120681 T1 HRP20120681 T1 HR P20120681T1 HR P20120681T T HRP20120681T T HR P20120681TT HR P20120681 T HRP20120681 T HR P20120681T HR P20120681 T1 HRP20120681 T1 HR P20120681T1
Authority
HR
Croatia
Prior art keywords
crystal
crystal according
ray powder
mixed
dihydroquinoline
Prior art date
Application number
HRP20120681TT
Other languages
English (en)
Croatian (hr)
Inventor
Satoh Motohide
Motomura Takahisa
Matsuda Takashi
Kondo Kentaro
Ando Koji
Matsuda Koji
Miyake Shuji
Uehara Hideto
Original Assignee
Japan Tobacco
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35079161&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20120681(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Japan Tobacco filed Critical Japan Tobacco
Publication of HRP20120681T1 publication Critical patent/HRP20120681T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
HRP20120681TT 2004-05-20 2005-05-19 Stabilni kristal 4-oksokinolinskog spoja HRP20120681T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004150979 2004-05-20
PCT/JP2005/009604 WO2005113508A1 (en) 2004-05-20 2005-05-19 Stable crystal of 4-oxoquinoline compound

Publications (1)

Publication Number Publication Date
HRP20120681T1 true HRP20120681T1 (hr) 2012-09-30

Family

ID=35079161

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20120681TT HRP20120681T1 (hr) 2004-05-20 2005-05-19 Stabilni kristal 4-oksokinolinskog spoja
HRP20231588TT HRP20231588T3 (hr) 2004-05-20 2005-05-19 Kombinacija koja sadrži stabilni kristal 4-oksokinolinskog spoja

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20231588TT HRP20231588T3 (hr) 2004-05-20 2005-05-19 Kombinacija koja sadrži stabilni kristal 4-oksokinolinskog spoja

Country Status (33)

Country Link
US (7) US7635704B2 (enExample)
EP (4) EP1636190B1 (enExample)
JP (1) JP3754064B2 (enExample)
KR (1) KR20080064909A (enExample)
CN (1) CN1956961B (enExample)
AR (2) AR049280A1 (enExample)
AU (1) AU2005245296B2 (enExample)
BE (1) BE2024C511I2 (enExample)
BR (1) BRPI0510114B8 (enExample)
CA (1) CA2566922C (enExample)
CY (4) CY1113010T1 (enExample)
DK (2) DK1636190T3 (enExample)
ES (2) ES2960824T3 (enExample)
FI (2) FI3281939T3 (enExample)
FR (1) FR23C1040I1 (enExample)
HR (2) HRP20120681T1 (enExample)
HU (2) HUE064615T2 (enExample)
IL (1) IL179250A0 (enExample)
LT (2) LT3281939T (enExample)
LU (1) LUC00334I2 (enExample)
MX (1) MXPA06013405A (enExample)
MY (1) MY134672A (enExample)
NO (8) NO339223B1 (enExample)
NZ (1) NZ551839A (enExample)
PE (2) PE20060358A1 (enExample)
PL (2) PL1636190T3 (enExample)
PT (2) PT3281939T (enExample)
RS (2) RS64845B1 (enExample)
RU (1) RU2330845C1 (enExample)
SI (2) SI3281939T1 (enExample)
TW (1) TWI329015B (enExample)
WO (1) WO2005113508A1 (enExample)
ZA (1) ZA200610647B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6891227B2 (en) 2002-03-20 2005-05-10 International Business Machines Corporation Self-aligned nanotube field effect transistor and method of fabricating same
US7176220B2 (en) * 2002-11-20 2007-02-13 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as pharmaceutical agent
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
WO2007063869A1 (ja) * 2005-11-30 2007-06-07 Japan Tobacco Inc. 高純度キノロン化合物の製造方法
US20070219243A1 (en) * 2005-12-30 2007-09-20 Kearney Brian P Method for improving the pharmacokinetics of HIV integrase inhibitors
AU2013203476C1 (en) * 2005-12-30 2016-11-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
US20090233964A1 (en) * 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
EP1978960A4 (en) * 2006-02-01 2009-12-02 Japan Tobacco Inc USE OF 6- (3-CHLORO-2-FLUORBENZYL) -1 - [(2S) -1-HYDROXY-3-METHYLBUTAN-2-YL [-7-METHOXY-4-OXO-1,4-DIHYDROCHINOLINE-3- CARBOXYLIC ACID OR SALT THEREOF FOR THE TREATMENT OF RETROVIRUS INFECTION
WO2007092802A1 (en) * 2006-02-09 2007-08-16 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and gs 9137
CN101437801B (zh) 2006-03-06 2013-02-06 日本烟草产业株式会社 制备4-氧代喹啉化合物的方法
JP4669040B2 (ja) * 2006-03-06 2011-04-13 日本たばこ産業株式会社 ４−オキソキノリン化合物の製造方法
KR101477822B1 (ko) 2006-07-07 2015-01-02 길리애드 사이언시즈, 인코포레이티드 치료제의 약동학 특성의 모듈레이터
ES2536923T3 (es) 2006-09-12 2015-05-29 Gilead Sciences, Inc. Proceso e intermedios para preparar inhibidores de la integrasa del VIH
PT3150586T (pt) 2007-02-23 2020-03-31 Gilead Sciences Inc Moduladores de propriedades farmacocinéticas de agentes terapêuticos
SG182229A1 (en) * 2007-06-29 2012-07-30 Gilead Sciences Inc Therapeutic compositions and the use thereof
WO2009006203A1 (en) * 2007-06-29 2009-01-08 Gilead Sciences, Inc. Therapeutic compositions and the use thereof
AR068403A1 (es) * 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
EA201591353A1 (ru) 2008-05-02 2016-01-29 Джилид Сайэнс, Инк. Применение частиц твердого носителя для улучшения технологических характеристик фармацевтического агента
PL2393485T3 (pl) 2009-02-06 2015-12-31 Gilead Sciences Inc Dwuwarstwowe tabletki zawierające elwitegrawir, kobicystat, emtrycytabinę i tenofowir
WO2010137032A2 (en) * 2009-05-14 2010-12-02 Matrix Laboratories Ltd. Novel polymorphic forms of elvitegravir and its pharmaceutically acceptable salts
WO2011004389A2 (en) * 2009-06-18 2011-01-13 Matrix Laboratories Ltd An improved process for the preparation of elvitegravir
CN102212032B (zh) * 2011-04-20 2013-07-31 复旦大学 一种5-羟基喹诺酮类衍生物及其制备方法和用途
US10071957B2 (en) 2012-07-06 2018-09-11 Genentech, Inc. N-substituted benzamides and methods of use thereof
EP2880017B1 (en) 2012-08-03 2016-10-05 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
CN103819402B (zh) * 2012-11-17 2016-03-30 上海迪赛诺化学制药有限公司 埃替拉韦中间体及其制备方法和应用
CN103864682B (zh) * 2012-12-18 2016-12-28 上海迪赛诺化学制药有限公司 一种制备iii型埃替拉韦晶体的方法
EA030003B1 (ru) 2012-12-21 2018-06-29 Джилид Сайэнс, Инк. Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции
NO2865735T3 (enExample) 2013-07-12 2018-07-21
DK3019503T3 (da) 2013-07-12 2017-11-20 Gilead Sciences Inc Polycykliske-carbamoylpyridon-forbindelser og anvendelse deraf til behandling af hiv-infektioner
CN105315203A (zh) * 2014-06-06 2016-02-10 上海迪赛诺化学制药有限公司 一种v型埃替拉韦晶体及其制备方法
NO2717902T3 (enExample) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
CA2980362C (en) 2015-04-02 2020-02-25 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EP4233846B1 (en) 2015-06-30 2024-12-04 Gilead Sciences, Inc. Pharmaceutical formulations
CN106008195B (zh) * 2016-05-19 2018-08-03 绍兴文理学院 一种2，4-二氟-5-碘苯甲酸的制备方法
EP3984536B1 (en) * 2020-10-19 2025-06-25 Centre national de la recherche scientifique Inhibition of the hiv-1 replication by compounds directed against a new target of the viral cycle

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3472859A (en) * 1966-11-01 1969-10-14 Sterling Drug Inc 1-alkyl-1,4-dihydro-4-oxo-3 quinoline-carboxylic acids and esters
JPS567162B1 (enExample) 1970-09-14 1981-02-16
JPS4826772A (enExample) 1971-08-11 1973-04-09
JPS6450979A (en) 1987-08-21 1989-02-27 Hitachi Shipbuilding Eng Co Method for discriminating whistle sound
JPH0651229B2 (ja) 1989-07-31 1994-07-06 新日本製鐵株式会社 プラズマアーク溶接方法および装置
IL100555A (en) 1991-02-07 2000-08-31 Hoechst Marion Roussel Inc N-substituted quinoline derivatives their preparation their use for the preparation of medicaments and the pharmaceutical compositions containing them
NO304832B1 (no) 1992-05-27 1999-02-22 Ube Industries Aminokinolonderivater samt middel mot HIV
JP2993316B2 (ja) 1992-05-27 1999-12-20 宇部興産株式会社 アリール基又は複素芳香環基置換アミノキノロン誘導体及びエイズ治療剤
JPH06199835A (ja) 1993-01-08 1994-07-19 Hokuriku Seiyaku Co Ltd ８−ジフルオロメトキシキノリン−３−カルボン酸誘導体
JPH06271568A (ja) 1993-03-22 1994-09-27 Hokuriku Seiyaku Co Ltd ７−フェニルピペラジニルキノリン−３−カルボン酸誘導体
RU2140919C1 (ru) 1994-07-18 1999-11-10 Убе Индастриз Лтд. Производные 8-трифторметилхинолинкарбоновой кислоты, фармацевтическая композиция и способ ингибирования вируса иммунодефицита
JP2930539B2 (ja) 1994-07-18 1999-08-03 三共株式会社 トリフルオロメチルキノリンカルボン酸誘導体
JPH0826772A (ja) 1994-07-22 1996-01-30 Sony Corp 融着用ガラス、その製造方法及び製造装置、並びに磁気ヘッドの製造方法
PT892801E (pt) 1996-04-12 2002-06-28 Us Gov Health & Human Serv Compostos derivados de acridona uteis como agentes antineoplasicos e antiretrovirais
FR2761687B1 (fr) * 1997-04-08 2000-09-15 Centre Nat Rech Scient Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques
JP3776203B2 (ja) 1997-05-13 2006-05-17 第一製薬株式会社 Ｉｃａｍ−１産生阻害剤
GB9721964D0 (en) 1997-10-16 1997-12-17 Pfizer Ltd Isoquinolines
US6399629B1 (en) 1998-06-01 2002-06-04 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
SE9802549D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6248736B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
US6248739B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
PE20011349A1 (es) 2000-06-16 2002-01-19 Upjohn Co 1-aril-4-oxo-1,4-dihidro-3-quinolincarboxamidas como agentes antivirales
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
AU2002230392A1 (en) 2000-10-12 2002-05-15 Merck & Co., Inc. AZA-and polyaza-naphthalenyl ketones useful as HIV integrase inhibitors
JP2004517860A (ja) 2000-10-12 2004-06-17 メルク　エンド　カムパニー　インコーポレーテッド Ｈｉｖインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルカルボキサミド類
CN1659143A (zh) 2001-03-01 2005-08-24 盐野义制药株式会社 具有hiv整合酶抑制活性的含氮杂芳基化合物
JP2002293745A (ja) 2001-03-29 2002-10-09 St Marianna Univ School Of Medicine 慢性関節リウマチ治療剤
US20030138483A1 (en) * 2001-05-25 2003-07-24 Sergio Petriconi Soft elastic capsules and compositions thereof
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
FR2827600A1 (fr) 2001-07-20 2003-01-24 Lipha Derives acides de quinolone et leurs applications en therapeutique
RU2206564C1 (ru) * 2002-03-07 2003-06-20 Общество с ограниченной ответственностью "Поливит" Способ получения этилового эфира 6-фтор-7-хлор-1,4-дигидро-4-оксо-3-хинолинкарбоновой кислоты
JP4035765B2 (ja) 2002-10-31 2008-01-23 横河電機株式会社 フーリエ変換型赤外線分光計
JP3567162B1 (ja) 2002-11-20 2004-09-22 日本たばこ産業株式会社 ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
US7176220B2 (en) 2002-11-20 2007-02-13 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as pharmaceutical agent
US7531554B2 (en) * 2004-05-20 2009-05-12 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as HIV integrase inhibitor
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
US8633219B2 (en) 2004-05-21 2014-01-21 Japan Tobacco Inc. Combination therapy

Also Published As

Publication number Publication date
EP4299563A2 (en) 2024-01-03
CA2566922A1 (en) 2005-12-01
HRP20231588T3 (hr) 2024-03-15
PL1636190T3 (pl) 2012-10-31
US20250091995A1 (en) 2025-03-20
CY2015009I2 (el) 2024-09-20
DK1636190T3 (da) 2012-09-24
NO20190051A1 (no) 2007-02-07
FIC20240008I1 (fi) 2024-03-20
MXPA06013405A (es) 2007-03-01
JP2006001927A (ja) 2006-01-05
LT3281939T (lt) 2023-11-27
NO20230913A1 (no) 2007-02-07
JP3754064B2 (ja) 2006-03-08
HUE064615T2 (hu) 2024-04-28
FR23C1040I1 (fr) 2023-12-29
RS64845B1 (sr) 2023-12-29
CY1113010T1 (el) 2016-04-13
US20180029989A1 (en) 2018-02-01
ES2960824T3 (es) 2024-03-06
DK3281939T3 (da) 2024-01-22
TWI329015B (en) 2010-08-21
LTC3281939I2 (enExample) 2025-04-25
US7635704B2 (en) 2009-12-22
SI3281939T1 (sl) 2024-02-29
CA2566922C (en) 2011-01-11
HK1083341A1 (en) 2006-06-30
EP3281939A1 (en) 2018-02-14
BRPI0510114B1 (pt) 2020-09-15
ES2388441T3 (es) 2012-10-15
US8981103B2 (en) 2015-03-17
HUS2400006I1 (hu) 2024-04-28
NO20161297A1 (no) 2007-02-07
EP1636190B1 (en) 2012-06-27
MY134672A (en) 2007-12-31
TW200600097A (en) 2006-01-01
PT3281939T (pt) 2023-11-22
PL3281939T3 (pl) 2024-03-18
LUC00334I2 (enExample) 2024-07-01
AU2005245296B2 (en) 2010-08-12
PE20060358A1 (es) 2006-05-12
RU2330845C1 (ru) 2008-08-10
PT1636190E (pt) 2012-08-20
NO20220690A1 (no) 2007-02-07
EP2514746A1 (en) 2012-10-24
NO347902B1 (no) 2024-05-06
PE20120361A1 (es) 2012-05-03
NO339223B1 (no) 2016-11-21
LTPA2024001I1 (enExample) 2024-04-10
NO20240384A1 (no) 2007-02-07
NO2024034I1 (no) 2024-07-15
CY2024008I1 (el) 2024-09-20
IL179250A0 (en) 2007-03-08
EP3281939B1 (en) 2023-10-18
EP4299563A3 (en) 2024-02-28
NO20065790L (no) 2007-02-07
SI1636190T1 (sl) 2012-09-28
AR049280A1 (es) 2006-07-12
AU2005245296A1 (en) 2005-12-01
US20150361044A1 (en) 2015-12-17
US20220235009A1 (en) 2022-07-28
BE2024C511I2 (enExample) 2024-10-08
NO20200873A1 (no) 2007-02-07
US20060030710A1 (en) 2006-02-09
CN1956961A (zh) 2007-05-02
AR096100A2 (es) 2015-12-09
FI3281939T3 (fi) 2023-10-23
US20190185433A1 (en) 2019-06-20
CY2015009I1 (el) 2024-09-20
WO2005113508A1 (en) 2005-12-01
US20100204271A1 (en) 2010-08-12
ZA200610647B (en) 2008-06-25
CY2024008I2 (el) 2024-09-20
BRPI0510114B8 (pt) 2021-05-25
CN1956961B (zh) 2010-05-26
EP1636190A1 (en) 2006-03-22
RS52375B (sr) 2012-12-31
KR20080064909A (ko) 2008-07-09
BRPI0510114A (pt) 2007-09-25
NZ551839A (en) 2009-11-27
CY1126560T1 (el) 2024-09-20

Similar Documents

Publication Publication Date Title
HRP20231588T3 (hr) Kombinacija koja sadrži stabilni kristal 4-oksokinolinskog spoja
GB2357083B (en) Nervonic acid derivatives, their preparation and use
CA2757418C (en) Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same
DK1373202T3 (da) Fremstilling af ikke-krystallinsk atorvastatincalcium
SI9620040B (sl) Postopek in kristalne oblike 2-metil-tieno-benzodiazepina
IL157534A (en) Atorvastatin calcium in a pharmaceutical form, composition thereof and pharmaceutical formulation comprising atorvastatin calcium
CA2446944A1 (en) Anti-inflammatory and immunomodulatory amino acid derivatives, their preparation and use
HRP20100455T1 (hr) Maleatne soli derivata kinazolina korisne kao antiangiogeno sredstvo
CA2453917A1 (en) Novel 2h-pyridazine-3-one derivatives, pharmaceutical compositions containing the same and a process for the preparation of the active ingredient
WO2004060376A8 (en) The r-isomer of beta amino acid compounds as integrin receptor antagonists derivatives
HRP20120700T1 (hr) SOLI SPOJEVA INHIBITORA HIV-a
HUP9701090A2 (hu) Mikropórusos kristályos anyag, eljárás ennek előállítására és detergens készítményekben való alkalmazása
CA2371789A1 (en) Novel guanidine derivatives as inhibitors of cell adhesion
HRP20121074T1 (hr) Derivati kinolina i njihovi farmaceutski sastavi
CN101463014A (zh) 二芳基苯并嘧啶类衍生物及其制备方法和用途
CA2562532C (en) Crystalline clopidogrel naphthalenesulfonate or hydrate thereof, method for preparing same and pharmaceutical composition containing same
HRP20110712T1 (hr) Novi postupak za dobivanje kristalnog oblika agomelatina
CA2370376A1 (en) Anhydrous mirtazapine crystals and process for the production thereof
HRP20131164T1 (hr) Delta kristalni oblik argininske soli perindoprila, postupak za njegovu pripremu i farmaceutske pripravke koji ga sadrže
MY134325A (en) Quinoline derivatives
NO983444D0 (no) Benzo(c)kinolizin derivater, deres fremstilling og anvendelse som 5<alfa>-reduktaseinhibitorer
BRPI9915682B8 (pt) modificação cristalina b de ácido 8-cian-1-ciclopropil-7-(1s, 6s-2,8-diazabiciclo-[4.3.0]nonan-8-il)-6-flúor-1,4-dihidro-4-oxo-3-quinolincarboxílico
CA2373962A1 (en) Immediate release medicinal compositions for oral use
HU210154B (en) Process for producing new famotidin-salts and pharmaceutical compositions of gastro-acid-secretion-inhibiting and gastro-citoprotective activity, containing them
DK1155018T3 (da) Krystalmodifikation C af 8-cyano-1-cyclopropyl-7-(1S, 6S-2,8- diazabicyclo [4.3.0]nonan-8-yl) -6-fluor-1,4-dihydro-4-oxo-3-quinolin-carboxylsyre